Next Article in Journal
Competition between H4PteGlu and H2PtePAS Confers para-Aminosalicylic Acid Resistance in Mycobacterium tuberculosis
Next Article in Special Issue
SWOT and Root Cause Analyses of Antimicrobial Resistance to Oral Antimicrobial Treatment of Cystitis
Previous Article in Journal
Dosage Optimisation of Trimethoprim and Sulfamethoxazole for the Treatment of an Avian Pathogenic Strain of Escherichia coli in Broiler Chickens
Previous Article in Special Issue
Alternative Antimicrobial Irrigation Strategies for the Treatment of Infections in Children: A Review of the Existing Literature
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Selective and Concentrative Enteropancreatic Recirculation of Antibiotics by Pigs

by
Karyl K. Buddington
1,
Stefan G. Pierzynowski
2,3,
William E. Holmes
4 and
Randal K. Buddington
5,6,*
1
Department of Biology, University of Memphis, Memphis, TN 38152, USA
2
Department of Biology, Lund University, Sölvegatan 35, 22362 Lund, Sweden
3
Department of Medical Biology, IMW, Jaczewskiego 2, 20-950 Lublin, Poland
4
Department of Chemical Engineering, University of Louisiana, Lafayette, LA 70503, USA
5
Department of Health Sciences, University of Memphis, Memphis, TN 38152, USA
6
Stonewall Research Facility, LSU Health Sciences, Stonewall, LA 71078, USA
*
Author to whom correspondence should be addressed.
Antibiotics 2024, 13(1), 12; https://doi.org/10.3390/antibiotics13010012
Submission received: 31 October 2023 / Revised: 13 December 2023 / Accepted: 16 December 2023 / Published: 21 December 2023

Abstract

:
Antibiotics that are efficacious for infectious pancreatitis are present in pancreatic exocrine secretion (PES) after intravenous administration and above minimal inhibitory concentrations. We measured concentrations of four antibiotics by tandem liquid chromatography–mass spectroscopy in plasma and PES after enteral administration to juvenile pigs with jugular catheters and re-entrant pancreatic-duodenal catheters. Nystatin, which is not absorbed by the intestine nor used for infectious pancreatitis (negative control), was not detected in plasma or PES. Concentrations of amoxicillin increased in plasma after administration (p = 0.035), but not in PES (p = 0.51). Metronidazole and enrofloxacin that are used for infectious pancreatitis increased in plasma after enteral administration and even more so in PES, with concentrations in PES averaging 3.1 (±0.5)- and 2.3 (±0.6)-fold higher than in plasma, respectively (p′s < 0.001). The increase in enrofloxacin in PES relative to plasma was lower after intramuscular administration (1.8 ± 0.5; p = 0.001). The present results demonstrate the presence of a selective and concentrative enteropancreatic pathway of secretion for some antibiotics. Unlike the regulated secretion of bile, the constitutive secretion of PES and intestinal reabsorption may provide a continuous exposure of pancreas tissue and the small intestine to recirculated antibiotics and potentially other therapeutic molecules. There is a need to better understand the enteropancreatic recirculation of antibiotics and the associated mechanisms.

1. Introduction

Antibiotics are an important component of therapy for treatment of pancreatitis associated with bacterial infection [1,2,3], though with some risk [4]. The selection of specific antibiotics for the treatment of infectious pancreatitis is largely based on a combination of bacterial sensitivity, penetration into pancreatic tissue after intravenous administration, and the presence in PES above minimal inhibitory concentrations [5]. More than seven decades of studies have screened numerous antibiotics and other therapeutic molecules for the ability to traverse the blood–pancreas–ductal epithelium barriers and enter the PES. Although some antibiotics can penetrate and accumulate in pancreas tissue, this may not coincide with transfer into the PES, apparently because of a ductal epithelial barrier that limits the transfer into the PES [6].
The recirculation of bile acids involving intestinal absorption, liver absorption from the blood, and secretion into the bile for return to the intestine (enterohepatic recirculation) is well recognized. The regulated secretion of bile is associated with secondary peaks in systemic concentrations and long terminal half-lives of elimination for some therapeutic compounds following oral administration [7,8,9]. The possibility of enteropancreatic recirculation (Figure 1) has not been directly evaluated. Suggestive evidence of enteropancreatic recirculation comes from antibiotics, such as fluoroquinolones and metronidazole, that are available in oral dosage forms because of intestinal absorption and appear in PES after intravenous administration [10,11,12,13] indicative of crossing the blood-pancreas-ductal epithelium barriers. Unlike the regulated secretion of bile, the constitutive component of PES, which includes continuous secretion of antimicrobial peptides [14,15,16], would provide a more consistent exposure of pancreas tissue, notably the ductal epithelium, and the small intestine to recirculated antibiotics and other therapeutic molecules.
The objective of the present study was to elucidate the presence and specificity of a pathway for enteropancreatic recirculation (Figure 1) by comparing the appearance of four antibiotics in plasma and PES after direct administration into the duodenum. Understanding the presence of enteropancreatic recirculation and associated exposure of the pancreatic ductal epithelium to antibiotics will enhance efforts to develop more effective antibiotics for treating infections associated with pancreatitis and potentially therapeutics for pancreatic ductal adenocarcinomas, the most common form of pancreatic cancer.
The four antibiotics selected (amoxicillin, metronidazole, enrofloxacin, nystatin) differ with respect to systemic availability after oral administration and reports of penetration into pancreatic tissue and secretion in PES when administered systemically. Metronidazole and the fluoroquinolone enrofloxacin penetrate into pancreatic tissue and appear in PES after intravenous administration and are used for bacterial associated pancreatitis [3,12,17]. Amoxicillin is absorbed by the intestine [18], but accumulation in pancreatic tissue is low compared to other antibiotics used for pancreatitis [19]. Nystatin is not absorbed appreciably by the intestine [20] and was selected as a negative control.
Pigs were selected as the model species because of translational relevance for gastroenterology physiology [21]. Importantly, the pancreatic duct of pigs is separate from the bile duct, allowing for serial collections of PES that is not contaminated by bile, which can be a significant pathway of antibiotic secretion into the intestine with higher concentrations of some antibiotics in bile than serum and PES [22]. The comparisons used healthy juvenile pigs with jugular catheters for collection of blood and re-entrant duodenum–pancreatic catheter systems [23] for direct administration of the antibiotics into the duodenum and for the collection of uncontaminated PES.

2. Results

The direct measurement of each antibiotic was performed using tandem liquid chromatography–mass spectroscopy. This provides a more accurate assessment than measuring antibacterial activity by the agar well diffusion method, which would include the endogenous antimicrobial activity of the PES [14,24] that is known to be present in pigs [15,16].
Nystatin. The selection of nystatin as a negative control for enteropancreatic recirculation was validated. Concentrations of nystatin in plasma after duodenal administration (0.015 μg/mL ± 0.030 for all post administration times; Figure 2) did not differ from background levels measured in the plasma of pigs receiving amoxicillin or enrofloxacin (p = 0.26). Nystatin in PES (0.015 μg/mL ± 0.034) did not exceed values measured in corresponding plasma samples (p = 0.84) or background levels in PES collected from pigs administered amoxicillin or enrofloxacin (p = 0.42). Hence, direct administration of nystatin into the duodenum did not result in a significant increase in plasma or PES concentrations relative to background levels.
Metronidazole. The highest concentrations of metronidazole were measured in samples of plasma and PES collected 20 min after duodenal administration (5.42 μg/mL ± 0.36 and 17.40 ± 1.30, respectively). Concentrations declined thereafter to 6 h (Figure 3A). Throughout the 6 h collection period, the concentrations measured in the PES exceeded those in plasma by an average of 3.1-fold (Figure 3B; p < 0.05). Hence, metronidazole is an example of an antibiotic that is rapidly absorbed by the intestine, appears in plasma, and is subsequently secreted in PES at concentrations that exceed those in plasma.
Enrofloxacin. Both routes of administration for enrofloxacin (duodenal and IM) increased concentrations in the plasma and PES (Figure 4A,B). Despite an IM dose that was 50% of the duodenal dose, plasma concentrations averaged 48% higher (±11% for all eight post-administration sampling times; p = 0.045) compared with administration into the duodenum. However, PES concentrations were not higher after IM administration compared with the duodenal dose (p = 0.63 for pooled data for all eight time points). Duodenal administration of enrofloxacin resulted in higher PES concentration during the first 2 h (Figure 4C). Over the entire 6 h collection period, ratios calculated from concentrations in PES relative to plasma averaged higher for the larger duodenal dose relative to intramuscular administration (2.32 ± 0.57 vs. 1.79 ± 0.53; p < 0.001).
Amoxicillin. Although plasma concentrations remained low after dosing (Figure 5), there was a slight but still significant increase compared with before dosing (p = 0.03). Furthermore, concentrations after dosing were higher than those measured in plasma collected from pigs after administering the other antibiotics (0.060 ± 0.092 vs. 0.023 ± 0.034; p = 0.002). These data indicate a limited amount of the amoxicillin dose was absorbed by the intestine. Concentrations of amoxicillin in the PES of dosed pigs were not higher than those measured in the plasma (p = 0.096) or in PES collected before administering the amoxicillin (p = 0.10) or the other antibiotics (p = 0.22). These findings suggest the pancreas has minimal ability to secrete amoxicillin in PES.
Glucose. Plasma concentrations of glucose were within the normal range of 100–120 mg/dL [25]. Glucose was not detected in the PES, implying the barrier between the blood and PES is selective.

3. Discussion

The use of healthy juvenile pigs avoids the confounding factors that complicate interpretations of data from human subjects being treated for pancreatitis, pancreatic cancer, necrotizing pancreatitis, or other pathologies that can disrupt the integrity of the pancreas and the ductal epithelial barrier and thereby affect penetration of antibiotics and other drugs into the pancreas and subsequent appearance into the PES. For example, patients with pancreatic fistulas have higher ciprofloxacin concentrations in bile and PES compared with serum 3 h after oral administration [26], whereas patients with a transplanted pancreas are unable to concentrate ciprofloxacin and pefloxacin in PES relative to serum [27,28,29]. Notably, pancreatitis alters tissue penetration [30,31], disrupts the tight junctions of the ductal epithelium [32], reduces secretion of immunoglobulin A in PES [33], thereby potentially compromises the recirculation of antibiotics.
The selective secretion of some antibiotics into PES after intravenous administration has been long recognized [10,34,35,36,37], with some antibiotics reaching concentrations in PES that are up to four-fold higher than in plasma. The higher concentrations of the chemotherapeutic agent 5-fluoruracil in PES relative to plasma [38] is another example of the capability of the pancreas ductal epithelium to selectively concentrate some therapeutic compounds in PES. The previous studies and the findings of this study confirm that the blood-pancreas-ductal epithelium pathway limits the transfer of some molecules from blood into the PES (e.g., glucose) with the ability to actively transport and concentrate others in the PES.
Metronidazole concentrations in most tissues are 60–100% of those measured in plasma [39]. Although saturable or concentrative mechanisms of transport have not been described for metronidazole, concentrative secretion of metronidazole has been reported for the gastric mucosa [40]. The two-fold higher concentrations of metronidazole measured in PES relative to plasma indicate the ductal epithelium of the pancreas has an active, carrier-mediated process capable of establishing a concentration gradient. Enrofloxacin and other fluoroquinolones have high tissue penetration [41]. The higher concentrations of enrofloxacin in PES compared with plasma indicate the basolateral and apical membranes of the ductal epithelium are capable of selective and concentrative secretion. Our findings that concentrations of metronidazole and enrofloxacin in PES after duodenal administration exceed those measured in plasma demonstrates a novel and previously unreported enteropancreatic recirculation pathway for these antibiotics and possibly other therapeutic compounds. This pathway may apply to the antibiotic trimethoprim that is absorbed after enteral administration [42] and achieves higher concentrations in PES than serum after intravenous administration [43]. Although oral doses of 5-fluoruracil cause intestinal damage [44], intestinal absorption of 5-fluoruracil [45] combined with the higher concentrations of 5-fluorouracil in PES than serum [38] are suggestive that enteropancreatic recirculation is possible for this chemotherapeutic agent. Importantly, enteropancreatic recirculation of antibiotics and other medications potentially prolongs exposure of the ductal epithelium to those antibiotics and medications and would extend the therapeutic half-life. The recirculation and concentrative secretion in PES corresponds with the recommended use of metronidazole and fluoroquinolones, such enrofloxacin and ciprofloxacin for treatment of infectious pancreatitis [3,17,46], although the efficacy has been questioned for prophylaxis [47].
The low plasma concentrations of amoxicillin measured in the pigs after duodenal administration is consistent with limited systemic bioavailability [48]. However, the low plasma appearance could have been due to competition for transporters between amoxicillin and components of the feed that was fed after administering the dose. This would explain why plasma concentrations of amoxicillin measured in the present pigs, despite a dose of 45 mg/kg, were markedly lower compared with pigs that were fasted and not fed after an oral dose of 20 mg/kg (0.06 μg/mL + 0.02 vs 3.14 µg/mL) [49,50]. Similarly, peak systemic bioavailability after providing an oral dose of 15 mg/kg amoxicillin to 25–35 kg pigs occurred before feeding [51]. The presence of a secretory pathway for amoxicillin has been speculated but ruled out for saliva and gastric juice [52]. The low PES concentrations of amoxicillin after an oral dose (present study) and for other β-lactams after intravenous administration [53,54] indicates transfer to PES is minimal, contributing to the minimal efficacy of amoxicillin for treating infectious pancreatitis.
Imipenem, a carbapenem member of beta-lactam antibiotics, is considered effective for infectious pancreatitis [55]. Like metronidazole and fluoroquinolones, imipenem is characterized by high penetration into pancreatic tissue [56,57] and secretion into PES [58]. The possibility of enteropancreatic recirculation needs to be evaluated for imipenem and other antibiotics used or considered for treatment of infectious pancreatitis.
Nystatin is not absorbed by the intestine, corresponding with the absence in plasma and PES samples, and is not used for fungal infections of the pancreas. Fluconazole is used to treat fungal infections and penetrates the pancreas and is present in PES after IV administration [59]. The availability of fluconazole after oral administration [60] suggests the possibility of enteropancreatic recirculation.
Potential mechanisms. Active concentrative secretion of bicarbonate by the ductal epithelium is well established [61] and involves activities of multiple proteins in the apical and basolateral membranes. There is interest in transporters for various solutes that are associated with the ductal epithelium as potential markers of pancreatic cancer and as therapeutic targets for more effective chemotherapeutic agents and protocols [62,63,64,65,66]. Although the mechanisms underlying the concentrative secretion by the ductal epithelium of some antibiotics into PES have not been elucidated, it is likely the secreted antibiotics share transporters identified for drugs [67,68]. Pancreatitis changes the expression of multiple solute transporters [69], and selective blocking of some solute transporters can exacerbate pancreatitis [70].
Intestinal absorption of fluoroquinolones is via organic anion transporters (OATs) in the apical membrane of enterocytes [71], whereas in breast tissue and liver enrofloxacin and other fluoroquinolones are substrates for ABC efflux transporters, corresponding with secretion of fluoroquinolones in milk and bile [72]. Saturable transport of the related ciprofloxacin by fibroblasts is responsible for secretion in gingival fluid [73], with concentrations up to four-fold higher than in plasma. The potential polarization of absorptive and secretory functions in the basolateral and apical membranes, respectively, of the ductal epithelium has not been elucidated. Although many oral and intravenous antibiotics appear in bile [74], fluoroquinolones, including enrofloxacin, do not achieve elevated concentrations in bile of rabbits [75]. This implies mechanisms of transepithelial movement differ for the selective transfer of some antibiotics into bile and PES.
Intestinal absorption of amoxicillin is by a combination of carrier-mediated (PepT1) and carrier-independent processes [76] and is considered to be saturable [77]. The lack of amoxicillin secretion in PES indicates either the absorptive or secretory mechanism necessary for secretion, or both, are absent in the ductal epithelium.
There is long-standing interest in understanding the transfer of antibiotics across the blood-brain and blood–cerebrospinal fluid barriers for the treatment of central nervous system infections [78,79,80]. These barriers involve another epithelium characterized by selective transfer of antibiotics via diffusion and energy-dependent transporters. Similar to the ductal epithelium of the pancreas, metronidazole and fluoroquinolones penetrate the BBB and achieve therapeutic levels in the cerebrospinal fluid, corresponding with transepithelial transfer from blood to cerebrospinal fluid [81]. The use of meropenem and vancomycin for CNS infections reflects a similar requirement to cross the BBB [79].
Limitations of the present study. The use of highly specific LC-MS ensured that the measured concentrations of the antibiotics in serum and PES represent the parent compounds and did not include the potential metabolites that possess antimicrobial activities. Hence, the antibiotic levels measured in PES may underestimate actual antimicrobial activity contributed by metabolites. Metronidazole is a prodrug that is bio transformed to multiple metabolites that are eliminated mainly in the urine [82,83]. Similarly, amoxicillin is subject to biotransformed [84,85] and eliminated after oral or systemic delivery to pigs [49]. Enrofloxacin is converted to ciprofloxacin, apparently in the liver [86,87], that can penetrate into pancreas tissue and PES after intravenous administration [11]. If ciprofloxacin, like enrofloxacin, is concentrated across the blood-pancreas ductal epithelium barrier, the combined concentrations of the parent compound and metabolites in PES could enhance the therapeutic dose in PES after intravenous, intramuscular, or oral administration of enrofloxacin. Interestingly, in the present study administration of enrofloxacin into the duodenum resulted in similar PES concentrations despite lower plasma concentrations compared to intramuscular injection. It is unknown if this reflects a maximum capacity to concentrate enrofloxacin in PES.
Differences exist among species for the secretion of antibiotics and other therapeutics into PES [88] and health states of the pancreas [89]. The species differences may reflect different anatomic arrangements, such as the common biliopancreatic duct in the rat versus separate biliary and pancreatic ducts with separate papillae in pigs and dogs. This is important as concentrations of some antibiotics in bile can exceed those in serum and PES, suggesting different concentrative capabilities exist for the pancreas and bile [22].

4. Conclusions

The ability of an antibiotic to penetrate pancreatic tissue is one determinant of efficacy for treatment of pancreatitis [56,90,91]. However, not all antibiotics that penetrate pancreas tissue enter the PES, suggesting there is an additional barrier associated with the ductal epithelium [6,22]. The present findings provide evidence that the ductal epithelium has selective mechanisms whereby some antibiotics that are absorbed by the intestine are transferred across the blood-pancreas-ductal epithelium barriers into PES at concentrations that can exceed those in plasma. The reabsorption of these antibiotics and associated antimicrobial metabolites by the intestine and re-secretion in PES potentially extends the therapeutic exposure of the infected pancreas. The enteropancreatic recirculation of enrofloxacin and metronidazole reported herein are consistent with the recommendation of the American Gastroenterological Association for the use of these two antibiotics for treating pancreatitis with concurrent infection [17]. The mechanisms responsible for the selective and concentrative transfer of antibiotics and other molecules from blood to PES remain mostly unknown. A better understanding will provide opportunities for improving the transfer of therapeutic compounds into the PES for treatment of infectious pancreatitis or for the retention of chemotherapeutics in ductal cells to treat pancreatic adenocarcinoma, as well as improving treatments for other diseases of the pancreas.

5. Materials and Methods

Animals. The studies reported herein used six healthy and recently weaned pigs obtained from a Swedish Landrace herd (Odarslöv’s Research Farm, Swedish University of Agricultural Sciences, Lund) with an average BW of 13.6 kg at the beginning of the experiment. The pigs were housed individually in pens (1 × 2 m), had free access to water, and were kept under 12 h light/12 h dark cycles (light on from 08.00 h to 20.00 h).
Surgical procedures. The pigs were sedated with azaperone (Stresnil, Janssen Pharmaceutica, Beerse, Belgium; 2 mg/kg BW), and anesthetization was induced with Halothane (ISC Chemicals Ltd., London, UK). Surgery was performed under aseptic conditions. The pigs were surgically fitted with a modification of a chronic pancreatic duct catheter with a T-shaped duodenal cannula for the collection and subsequent return of pancreatic juice into the duodenum [23,92]. The pigs were allowed to recover for one week after the surgery before the study was started. The pigs were not treated with antibiotics after surgery.
Selection and administration of antibiotics and collection of samples. Metronidazole (Flagyl®; MW = 171 g/mol) was selected as a candidate for enteropancreatic recirculation because of its high oral bioavailability [39], known penetration into pancreas tissue and appearance in PES after IV administration [10,13], and reported efficacy for treating anaerobic infections associated with pancreatitis [2]. In contrast, Nystatin (MW = 926) is poorly absorbed across mucous membranes and was selected as a negative control for intestinal absorption. The expectation was that after administration of Nystatin into the duodenum, concentrations would be negligible in plasma and PES. Metronidazole and Nystatin were co-administered via the duodenal catheter at dosages of 25 mg/kg and 40 mg/kg (200,000 units/kg), respectively.
Amoxicillin is absorbed by the intestine better than other β-lactam antibiotics but has low penetration into pancreatic tissue [18]. It was anticipated that after administering 45 mg/kg via the duodenal catheter, amoxicillin would be detected in the blood, but concentrations in the PES would be low or undetectable.
Enrofloxacin (Baytril®; MW 359 g/mol) is a fluoroquinolone used orally and intravenously for infections in animals. The efficacy of the metabolite ciprofloxacin used clinically as a prophylactic for acute necrotizing pancreatitis has been questioned, since bacterial infection is often not a contributing cause of morbidity in acute pancreatitis [93]. Nonetheless, fluoroquinolones penetrate pancreas tissue [5] and can effectively treat bacterial infections of the pancreas [2]. Ciprofloxacin has been detected in the intestinal contents of pigs after intramuscular injection [94], indicating that pancreatic secretion contributes to its elimination, but the relative contributions of biliary, pancreatic, and intestinal secretion were not determined. Enrofloxacin has been found in bile [86], but its pharmacokinetics are not affected by liver damage [87], suggesting there may be an alternative route for the recirculation of enrofloxacin, specifically via the PES. A suspension of Enrofloxacin (Baytril®; Elanco Animal Health, Greenfield, IN, USA) was prepared by pulverizing tablets, dissolving the powder in water, and injected via the duodenal catheter to provide a dose of 5 mg/kg. In addition, a commercially available injectable suspension of 22.7 mg/mL Enrofloxacin was injected intramuscularly (IM) at a dose of 2.5 mg/kg. The dose was administered IM, not intravenously, to avoid the contamination of the jugular catheter with Enrofloxacin.
The antibiotics were administered between 0800 and 0900 prior to feeding. Each antibiotic was administered to three pigs, and each pig was used to study two antibiotics, with a minimum of 3 intervening days between the administration of the first and second antibiotics. Collections of PES and blood (with EDTA for isolation of plasma) were made immediately before administration to obtain baseline values and at 20, 40, and 60 min after administration and hourly thereafter to 6 h. The pigs were provided food after administration of the antibiotic(s). The PES and plasma samples were frozen (−80 °C) until analyzed.
Analytical procedures. Each of the collected plasma and PES samples were analyzed for all four antibiotics. PES was diluted 1:9 in 1M Tris Buffer (pH 7.4) and plasma in acetonitrile (1:9). After centrifugation (13,000× g; 10 min, 4 °C), the supernatants were filtered (0.45 μm PTFE filter), separated using RP-HPLC (Restek Allure PFP Propyl 3 μm 100 × 2.1 mm column using Varian ProStar 210 solvent delivery system at 0.2 mL/min), and analyzed by MS/MS (Bruker Esquire; 4.5 kV ionization energy, positive ionization, 30 PSI nebulizer, 10.0 L/min dry gas and 325 °C). Each run included a standard curve with antibiotic concentrations (ng/mL) of 3.13, 6.25, 12.5, 25.0, and 50. A buffer blank was included before each time series for a pig. Spiked samples of either PES or serum corresponding with sample type were included at the end of the time series to evaluate accuracy, reproducibility, and recovery. The 95% detection limit confidences were established for each antibiotic.
Glucose was measured using a commercial kit in 5 concurrently collected pairs of PES and plasma samples. This was done to obtain additional insights about the selectivity of the appearance of the antibiotics and glucose in the PES.

Author Contributions

Conceptualization, K.K.B.; methodology, K.K.B., S.G.P., R.K.B. and W.E.H.; formal analysis, W.E.H.; resources, S.G.P. and W.E.H.; data curation, R.K.B. and W.E.H.; writing—original draft preparation, R.K.B.; writing—review and editing, K.K.B., S.G.P. and W.E.H.; visualization, R.K.B. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was approved by the Animal Ethics Committee of the University of Lund, Sweden, No. M124-09.

Data Availability Statement

All data collected and analyzed during this study are presented in this published article.

Acknowledgments

This contribution is dedicated to the memory of Karyl K Buddington and her dedication to improving the care and health of animals and humans. Autumn Sanderson created Figure 1.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Firsova, V.G.; Parshikov, V.V.; Kukosh, M.V.; Mukhin, A.S. Antibacterial and Antifungal Therapy for Patients with Acute Pancreatitis at High Risk of Pancreatogenic Sepsis (Review). Sovrem Tekhnologii Med. 2020, 12, 126–136. [Google Scholar] [CrossRef] [PubMed]
  2. Rasslan, R.; Novo, F.D.C.F.; Bitran, A.; Utiyama, E.M.; Rasslan, S. Management of infected pancreatic necrosis: State of the art. Rev. Col. Bras. Cir. 2017, 44, 521–529. [Google Scholar] [CrossRef] [PubMed]
  3. Severino, A.; Varca, S.; Airola, C.; Mezza, T.; Gasbarrini, A.; Franceschi, F.; Candelli, M.; Nista, E.C. Antibiotic Utilization in Acute Pancreatitis: A Narrative Review. Antibiotics 2023, 12, 1120. [Google Scholar] [CrossRef] [PubMed]
  4. Del Gaudio, A.; Covello, C.; Di Vincenzo, F.; De Lucia, S.S.; Mezza, T.; Nicoletti, A.; Siciliano, V.; Candelli, M.; Gasbarrini, A.; Nista, E.C. Drug-Induced Acute Pancreatitis in Adults: Focus on Antimicrobial and Antiviral Drugs, a Narrative Review. Antibiotics 2023, 12, 1495. [Google Scholar] [CrossRef] [PubMed]
  5. Bassi, C.; Falconi, C.; Casetti, L.; Valerio, A.; Caldiron, E.; Butturini, G.; Pederzoli, P. Antibiotics in severe pancreatitis: The current status. HPB 1999, 1, 57–60. [Google Scholar] [CrossRef]
  6. Burns, G.P.; Stein, T.A.; Kabnick, L.S. Blood-pancreatic juice barrier to antibiotic excretion. Am. J. Surg. 1986, 151, 205–208. [Google Scholar] [CrossRef] [PubMed]
  7. Ibarra, M.; Trocóniz, I.F.; Fagiolino, P. Enteric reabsorption processes and their impact on drug pharmacokinetics. Sci. Rep. 2021, 11, 5794. [Google Scholar] [CrossRef]
  8. Malik, M.Y.; Jaiswal, S.; Sharma, A.; Shukla, M.; Lal, J. Role of enterohepatic recirculation in drug disposition: Cooperation and complications. Drug Metab. Rev. 2016, 48, 281–327. [Google Scholar] [CrossRef]
  9. Okusanya, O.; Forrest, A.; DiFrancesco, R.; Bilic, S.; Rosenkranz, S.; Para, M.F.; Adams, E.; Yarasheski, K.E.; Reichman, R.C.; Morse, G.D. Compartmental Pharmacokinetic Analysis of Oral Amprenavir with Secondary Peaks. Antimicrob. Agents Chemother. 2007, 51, 1822–1826. [Google Scholar] [CrossRef]
  10. Wallace, J.R.; Cushing, R.D.; E Bawdon, R.; Sugawa, C.; E Lucas, C.; Ledgerwood, A.M. Assessment of antimicrobial penetrance into the pancreatic juice in humans. Surg. Gynecol. Obstet. 1986, 162, 313–316. [Google Scholar]
  11. Isenmann, R.; Fleischer, K.; Schlegel, P.; Frieß, H.; Büchler, M.W. Penetration of ciprofloxacin into the human pancreas. Infection 1994, 22, 343–346. [Google Scholar] [CrossRef] [PubMed]
  12. Wicha, S.G.; Mundkowski, R.G.; Klock, A.; Hopt, U.T.; Drewelow, B.; Kloft, C.; Wellner, U.F.; Keck, T.; Wittel, U.A. Is Moxifloxacin a Treatment Option for Pancreatic Infections? A Pharmacometric Analysis of Serum and Pancreatic Juice. J. Clin. Pharmacol. 2019, 59, 1405–1414. [Google Scholar] [CrossRef] [PubMed]
  13. Büchler, M.; Frieß, H.; Bittner, R.; Beger, H.G.; Malfertheiner, P.; Vanek, E.; Schlegel, P. The penetration of antibiotics into human pancreas. Infection 1989, 17, 20–25. [Google Scholar] [CrossRef] [PubMed]
  14. Ahuja, M.; Schwartz, D.M.; Tandon, M.; Son, A.; Zeng, M.; Swaim, W.; Eckhaus, M.; Hoffman, V.; Cui, Y.; Xiao, B.; et al. Orai1-Mediated Antimicrobial Secretion from Pancreatic Acini Shapes the Gut Microbiome and Regulates Gut Innate Immunity. Cell Metab. 2017, 25, 635–646. [Google Scholar] [CrossRef] [PubMed]
  15. Holowachuk, S.A.; Bal’A, M.F.; Gerard, P.D.; Buddington, R.K. Nonparallel Secretion of Antibacterial Activity and Protein in Porcine Pancreatic Juice. Pancreas 2004, 28, e32–e38. [Google Scholar] [CrossRef] [PubMed]
  16. Kruszewska, D.; Ljungh, Å.; Hynes, S.O.; Pierzynowski, S.G. Effect of the antibacterial activity of pig pancreatic juice on human multiresistant bacteria. Pancreas 2004, 28, 191–199. [Google Scholar] [CrossRef] [PubMed]
  17. Baron, T.H.; DiMaio, C.J.; Wang, A.Y.; Morgan, K.A. American Gastroenterological Association Clinical Practice Update: Management of Pancreatic Necrosis. Gastroenterology 2020, 158, 67–75.e1. [Google Scholar] [CrossRef]
  18. Barr, W.H.; Zola, E.M.; Candler, E.L.; Hwang, S.-M.; Tendolkar, A.V.; Shamburek, R.; Parker, B.; Hilty, M.D. Differential absorption of amoxicillin from the human small and large intestine. Clin. Pharmacol. Ther. 1994, 56, 279–285. [Google Scholar] [CrossRef]
  19. Spicák, J.; Martínek, J.; Závada, F.; Morávek, J.; Melenovsky, V. Penetration of antibiotics into the pancreas in rats: An effect of acute necrotizing pancreatitis. Scand. J. Gastroenterol. 1999, 34, 92–97. [Google Scholar]
  20. Samaranayake, L.P.; Leung, W.K.; Jin, L. Oral mucosal fungal infections. Periodontology 2000 2009, 49, 39–59. [Google Scholar] [CrossRef]
  21. Ziegler, A.; Gonzalez, L.; Blikslager, A. Large Animal Models: The Key to Translational Discovery in Digestive Disease Research. Cell. Mol. Gastroenterol. Hepatol. 2016, 2, 716–724. [Google Scholar] [CrossRef] [PubMed]
  22. Burns, G.P.; Stein, T.A.; Cohen, M. Biliary and pancreatic excretion of cefamandole. Antimicrob. Agents Chemother. 1989, 33, 977–979. [Google Scholar] [CrossRef] [PubMed]
  23. Pierzynowski, S.G.; Weström, B.R.; Karlsson, B.W.; Nilsson, B.; Svendsen, J. Pancreatic cannulation of young pigs for long-term study of exocrine pancreatic function. Can. J. Anim. Sci. 1988, 68, 953–959. [Google Scholar] [CrossRef]
  24. Minelli, E.B.; Benini, A.; Bassi, C.; Abbas, H.; Falconi, M.; Locatelli, F.; de Marco, R.; Pederzoli, P. Antimicrobial activity of human pancreatic juice and its interaction with antibiotics. Antimicrob. Agents Chemother. 1996, 40, 2099–2105. [Google Scholar] [CrossRef] [PubMed]
  25. Ventrella, D.; Dondi, F.; Barone, F.; Serafini, F.; Elmi, A.; Giunti, M.; Romagnoli, N.; Forni, M.; Bacci, M.L. The biomedical piglet: Establishing reference intervals for haematology and clinical chemistry parameters of two age groups with and without iron supplementation. BMC Veter- Res. 2016, 13, 23. [Google Scholar] [CrossRef] [PubMed]
  26. Pederzoli, P.; Falconi, M.; Bassi, C.; Vesentini, S.; Orcalli, F.; Scaglione, F.; Solbiati, M.; Messori, A.; Martini, N. Ciprofloxacin Penetration in Pancreatic Juice. Chemotherapy 1987, 33, 397–401. [Google Scholar] [CrossRef] [PubMed]
  27. Brattström, C.; Malborg, A.S.; Tydén, G. Penetration of ciprofloxacin and ofloxacin into pancreatic juice. Chemioter. Int. J. Mediterr. Soc. Chemother. 1987, 6, 295–297. [Google Scholar]
  28. Brattström, C.; Malmborg, A.-S.; Tydén, G. Penetration of ciprofloxacin and ofloxacin into human allograft pancreatic juice. J. Antimicrob. Chemother. 1988, 22, 213–219. [Google Scholar] [CrossRef]
  29. Malmborg, A.-S.; Brattström, C.; Tydén, G. Penetration of pefloxacin into human allograft pancreatic juice. J. Antimicrob. Chemother. 1990, 25, 393–397. [Google Scholar] [CrossRef]
  30. Bassi, C.; Pederzoli, P.; Vesentini, S.; Falconi, M.; Bonora, A.; Abbas, H.; Benini, A.; Bertazzoni, E.M. Behavior of antibiotics during human necrotizing pancreatitis. Antimicrob. Agents Chemother. 1994, 38, 830–836. [Google Scholar] [CrossRef]
  31. Fanning, K.J.; Robertson, T.A.; Prins, J.B.; Roberts, M.S. Changes in Antibiotic Distribution Due to Pancreatitis. Antimicrob. Agents Chemother. 2011, 55, 3008–3011. [Google Scholar] [CrossRef] [PubMed]
  32. Kojima, T.; Yamaguchi, H.; Ito, T.; Kyuno, D.; Kono, T.; Konno, T.; Sawada, N. Tight junctions in human pancreatic duct epithelial cells. Tissue Barriers 2013, 1, e24894. [Google Scholar] [CrossRef] [PubMed]
  33. Emmrich, J.; Seyfarth, M.; Conradi, P.; Plath, F.; Sparmann, G.; Löhr, M.; Liebe, S. Secretory immunoglobulin A in pancreatic juice and pancreatic tissue of patients with chronic pancreatitis. Gut 1998, 42, 436–441. [Google Scholar] [CrossRef] [PubMed]
  34. A Dainko, E.; Gabel, A.; A Paul, H.; Beattie, E.J. Experimental pancreatic fistula; comparative secretion of antibacterial agents in the dog. Presbyt. St Lukes. Hosp. Med. Bull. 1963, 2, 159–166. [Google Scholar] [PubMed]
  35. Gerber, B.; Silverman, M.; Preston, F.W. The excretion of antibiotics in pancreatic fluid. Surg. Forum 1957, 8, 261–266. [Google Scholar] [PubMed]
  36. Preston, F.W.; Silverman, M.; Henegar, G.C. Excretion of Antibiotics in Pancreatic Fluid. Arch. Surg. 1959, 78, 810–814. [Google Scholar] [CrossRef] [PubMed]
  37. Rumore, P.C.; Olander, G.A.; Puestow, C.B. Excretion of antibiotics, dyes, and radioactive substances through external pancreatic fistula. Surgery 1953, 34, 735–741. [Google Scholar]
  38. Zhu, Z.; Fu, Q.; Nightingale, C.H.; Zhao, Y.P.; Liao, Q.; Wang, H.N.; Xue, C.Q.; Yang, Z.Y.; Li, D.K. Pharmacokinetics of 5-fluorouracil and its penetration into pancreatic juice in dogs. Zhongguo Yao Li Xue Bao 1998, 19, 7–9. [Google Scholar]
  39. Lamp, K.C.; Freeman, C.D.; Klutman, N.E.; Lacy, M.K. Pharmacokinetics and Pharmacodynamics of the Nitroimidazole Antimicrobials. Clin. Pharmacokinet. 1999, 36, 353–373. [Google Scholar] [CrossRef]
  40. Calafatti, S.A. Transfer of metronidazole to gastric juice: Impact of Helicobacter pylori infection and omeprazole. Scand. J. Gastroenterol. 2000, 35, 699–704. [Google Scholar] [CrossRef]
  41. Turnidge, J. Pharmacokinetics and Pharmacodynamics of Fluoroquinolones. Drugs 1999, 58, 29–36. [Google Scholar] [CrossRef] [PubMed]
  42. Autmizguine, J.; Melloni, C.; Hornik, C.P.; Dallefeld, S.; Harper, B.; Yogev, R.; Sullivan, J.E.; Atz, A.M.; Al-Uzri, A.; Mendley, S.; et al. Population Pharmacokinetics of Trimethoprim-Sulfamethoxazole in Infants and Children. Antimicrob. Agents Chemother. 2018, 62, e01813-17. [Google Scholar] [CrossRef] [PubMed]
  43. Vergin, H.; Bishop-Freudling, G.B.; Merk, K.; Szelenyi, I. Pancreatic secretion of benzylpyrimidines. Experimental studies in dogs. Arzneimittelforschung 1982, 32, 1302–1304. [Google Scholar] [PubMed]
  44. Yotsumoto, K.; Akiyoshi, T.; Wada, N.; Imaoka, A.; Ohtani, H. 5-Fluorouracil treatment alters the expression of intestinal transporters in rats. Biopharm. Drug Dispos. 2017, 38, 509–516. [Google Scholar] [CrossRef] [PubMed]
  45. Yuasa, H.; Matsuda, K.; Gu, J.; Suzuki, E.; Yokouchi, I.; Watanabe, J. Dose-Dependent Gastrointestinal Absorption of 5-Fluorouracil in Rats In Vivo. Biol. Pharm. Bull. 1996, 19, 1494–1498. [Google Scholar] [CrossRef]
  46. De Campos, T.; Rasslan, S.A.J.F.; Rasslan, S. Questions about the use of antibiotics in acute pancreatitis. World J. Emerg. Surg. 2006, 1, 20. [Google Scholar] [CrossRef]
  47. Dambrauskas, Z.; Gulbinas, A.; Pundzius, J.; Barauskas, G. Meta-analysis of prophylactic parenteral antibiotic use in acute necrotizing pancreatitis. Medicina 2007, 43, 291. [Google Scholar] [CrossRef]
  48. Chesa-Jiménez, J.; E Peris, J.; Torres-Molina, F.; Granero, L. Low bioavailability of amoxicillin in rats as a consequence of presystemic degradation in the intestine. Antimicrob. Agents Chemother. 1994, 38, 842–847. [Google Scholar] [CrossRef]
  49. Martínez-Larrañaga, M.R.; Anadón, A.; Martínez, M.A.; Díaz, M.J.; Frejo, M.T.; Castellano, V.J.; Isea, G.; De la Cruz, C.O. Pharmacokinetics of amoxycillin and the rate of depletion of its residues in pigs. Vet Rec. 2004, 154, 627–632. [Google Scholar] [CrossRef]
  50. Reyns, T.; De Boever, S.; De Baere, S.; De Backer, P.; Croubels, S. Tissue Depletion of Amoxicillin and Its Major Metabolites in Pigs: Influence of the Administration Route and the Simultaneous Dosage of Clavulanic Acid. J. Agric. Food Chem. 2007, 56, 448–454. [Google Scholar] [CrossRef]
  51. Reyns, T.; DE Boever, S.; Schauvliege, S.; Gasthuys, F.; Meissonnier, G.; Oswald, I.; DE Backer, P.; Croubels, S. Influence of administration route on the biotransformation of amoxicillin in the pig. J. Veter- Pharmacol. Ther. 2009, 32, 241–248. [Google Scholar] [CrossRef]
  52. Ortiz, R.A.M.; Calafatti, S.A.; Corazzi, A.; Souza, J.M.; Deguer, M.; De Souza, C.A.F.; Marchioretto, M.A.M.; Bernasconi, G.; Ferraz, J.G.P.; Pedrazzoli, J., Jr. Amoxicillin and ampicillin are not transferred to gastric juice irrespective of Helicobacter pylori status or acid blockade by omeprazole. Aliment. Pharmacol. Ther. 2002, 16, 1163–1170. [Google Scholar] [CrossRef] [PubMed]
  53. Gregg, J.A.; Maher, L.; DeGirolami, P.C.; Gregg, J.A., Jr. Secretion of beta-lactam antibiotics in pure human pancreatic juice. Am. J. Surg. 1985, 150, 333–335. [Google Scholar] [CrossRef] [PubMed]
  54. Roberts, E.A.; Williams, R.J. Ampicillin Concentrations in Pancreatic Fluid Bile Obtained at Endoscopic Retrograde Cholangiopancreatography (ERCP). Scand. J. Gastroenterol. 1979, 14, 669–672. [Google Scholar] [CrossRef] [PubMed]
  55. Bassi, C.; Falconi, M.; Talamini, G.; Uomo, G.; Papaccio, G.; Dervenis, C.; Salvia, R.; Minelli, E.B.; Pederzoli, P. Controlled clinical trial of pefloxacin versus imipenem in severe acute pancreatitis. Gastroenterology 1998, 115, 1513–1517. [Google Scholar] [CrossRef] [PubMed]
  56. Büchler, M.; Malfertheiner, P.; Frieβ, H.; Isenmann, R.; Vanek, E.; Grimm, H.; Schlegel, P.; Friess, T.; Beger, H.G. Human pancreatic tissue concentration of bactericidal antibiotics. Gastroenterology 1992, 103, 1902–1908. [Google Scholar] [CrossRef] [PubMed]
  57. Guo, D.; Dai, W.; Shen, J.; Zhang, M.; Shi, Y.; Jiang, K.; Guo, L. Assessment of Prophylactic Carbapenem Antibiotics Administration for Severe Acute Pancreatitis: An Updated Systematic Review and Meta-Analysis. Digestion 2022, 103, 183–191. [Google Scholar] [CrossRef]
  58. Brattström, C.; Malmborg, A.-S.; Tydén, G. Penetration of Imipenem into Human Pancreatic Juice following Single Intravenous Dose Administration1. Chemotherapy 1989, 35, 83–87. [Google Scholar] [CrossRef]
  59. Shrikhande, S.; Friess, H.; Issenegger, C.; Martignoni, M.E.; Yong, H.; Gloor, B.; Yeates, R.; Kleeff, J.; Büchler, M.W. Fluconazole Penetration into the Pancreas. Antimicrob. Agents Chemother. 2000, 44, 2569–2571. [Google Scholar] [CrossRef]
  60. Buijk, S.; Gyssens, I.; Mouton, J.; Verbrugh, H.; Touw, D.; Bruining, H. Pharmacokinetics of sequential intravenous and enteral fluconazole in critically ill surgical patients with invasive mycoses and compromised gastro-intestinal function. Intensiv. Care Med. 2001, 27, 115–121. [Google Scholar] [CrossRef]
  61. Ishiguro, H.; Yamamoto, A.; Nakakuki, M.; Yi, L.; Ishiguro, M.; Yamaguchi, M.; Kondo, S.; Mochimaru, Y. Physiology and pathophysiology of bicarbonate secretion by pancreatic duct epithelium. Nagoya J. Med. Sci. 2012, 74, 1–18. [Google Scholar] [PubMed]
  62. Lemstrová, R.; Souček, P.; Melichar, B.; Mohelnikova-Duchonova, B.; Giovannetti, E.; Pacetti, P.; Reni, M.; Leon, L.G.; Mambrini, A.; Vasile, E.; et al. Role of solute carrier transporters in pancreatic cancer: A review. Pharmacogenomics 2014, 15, 1133–1145. [Google Scholar] [CrossRef] [PubMed]
  63. Wu, Z.; Xu, J.; Liang, C.; Meng, Q.; Hua, J.; Wang, W.; Zhang, B.; Liu, J.; Yu, X.; Shi, S. Emerging roles of the solute carrier family in pancreatic cancer. Clin. Transl. Med. 2021, 11, e356. [Google Scholar] [CrossRef] [PubMed]
  64. Sahores, A.; Carozzo, A.; May, M.; Gómez, N.; Di Siervi, N.; De Sousa Serro, M.; Yaneff, A.; Rodríguez-González, A.; Abba, M.; Shayo, C.; et al. Multidrug transporter MRP4/ABCC4 as a key determinant of pancreatic cancer aggressiveness. Sci. Rep. 2020, 10, 14217. [Google Scholar] [CrossRef] [PubMed]
  65. Koltai, T.; Reshkin, S.J.; Carvalho, T.M.A.; Di Molfetta, D.; Greco, M.R.; Alfarouk, K.O.; Cardone, R.A. Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review. Cancers 2022, 14, 2486. [Google Scholar] [CrossRef] [PubMed]
  66. Carter, C.J.; Mekkawy, A.H.; Morris, D.L. Role of human nucleoside transporters in pancreatic cancer and chemoresistance. World J. Gastroenterol. 2021, 27, 6844–6860. [Google Scholar] [CrossRef]
  67. Hua, W.J.; Hua, W.X.; Jian, Z.; Wei, P.H.; Ni, L.Y.; Hua, L.Y.; Wen, C.D.; Ying, Z.; Li, C. The Role of Drug Transporters in the Pharmacokinetics of Antibiotics. Curr. Drug Metab. 2016, 17, 799–805. [Google Scholar] [CrossRef] [PubMed]
  68. Nigam, S.K.; Bush, K.T.; Martovetsky, G.; Ahn, S.-Y.; Liu, H.C.; Richard, E.; Bhatnagar, V.; Wu, W. The Organic Anion Transporter (OAT) Family: A Systems Biology Perspective. Physiol. Rev. 2015, 95, 83–123. [Google Scholar] [CrossRef]
  69. Schaarschmidt, T.; Merkord, J.; Adam, U.; Schroeder, E.; Kunert-Keil, C.; Sperker, B.; Drewelow, B.; Wacke, R. Expression of Multidrug Resistance Proteins in Rat and Human Chronic Pancreatitis. Pancreas 2004, 28, 45–52. [Google Scholar] [CrossRef]
  70. Ventimiglia, M.S.; Najenson, A.C.; Perazzo, J.C.; Carozzo, A.; Vatta, M.S.; Davio, C.A.; Bianciotti, L.G. Blockade of Multidrug Resistance-Associated Proteins Aggravates Acute Pancreatitis and Blunts Atrial Natriuretic Factor’s Beneficial Effect in Rats: Role of MRP4 (ABCC4). Mol. Med. 2015, 21, 58–67. [Google Scholar] [CrossRef]
  71. Arakawa, H.; Shirasaka, Y.; Haga, M.; Nakanishi, T.; Tamai, I. Active intestinal absorption of fluoroquinolone antibacterial agent ciprofloxacin by organic anion transporting polypeptide, Oatp1a5. Biopharm. Drug Dispos. 2012, 33, 332–341. [Google Scholar] [CrossRef] [PubMed]
  72. Alvarez, A.I.; Pérez, M.; Prieto, J.G.; Molina, A.J.; Real, R.; Merino, G. Fluoroquinolone Efflux Mediated by ABC Transporters. J. Pharm. Sci. 2008, 97, 3483–3493. [Google Scholar] [CrossRef] [PubMed]
  73. Lavda, M.; Clausnitzer, C.E.; Walters, J.D. Distribution of Systemic Ciprofloxacin and Doxycycline to Gingiva and Gingival Crevicular Fluid. J. Periodontol. 2004, 75, 1663–1667. [Google Scholar] [CrossRef] [PubMed]
  74. Thabit, A.K. Antibiotics in the Biliary Tract: A Review of the Pharmacokinetics and Clinical Outcomes of Antibiotics Penetrating the Bile and Gallbladder Wall. Pharmacother. J. Hum. Pharmacol. Drug Ther. 2020, 40, 672–691. [Google Scholar] [CrossRef] [PubMed]
  75. Shimada, S.; Aboubakr, M.; Elbadawy, M.; Usui, T.; Sasaki, K.; Shimoda, M. Biliary excretion and pharmacokinetics of several fluoroquinolones after intravenous injection in rabbits. J. Vet. Med. Sci. 2023, 85, 1099–1105. [Google Scholar] [CrossRef]
  76. Legen, I.; Kračun, M.; Salobir, M.; Kerč, J. The evaluation of some pharmaceutically acceptable excipients as permeation enhancers for amoxicillin. Int. J. Pharm. 2006, 308, 84–89. [Google Scholar] [CrossRef]
  77. de Velde, F.; de Winter, B.C.; Koch, B.C.; van Gelder, T.; Mouton, J.W. Non-linear absorption pharmacokinetics of amoxicillin: Consequences for dosing regimens and clinical breakpoints. J. Antimicrob. Chemother. 2016, 71, 2909–2917. [Google Scholar] [CrossRef]
  78. Haddad, N.; Carr, M.; Balian, S.; Lannin, J.; Kim, Y.; Toth, C.; Jarvis, J. The Blood–Brain Barrier and Pharmacokinetic/Pharmacodynamic Optimization of Antibiotics for the Treatment of Central Nervous System Infections in Adults. Antibiotics 2022, 11, 1843. [Google Scholar] [CrossRef]
  79. Schneider, F.; Gessner, A.; El-Najjar, N. Efficacy of Vancomycin and Meropenem in Central Nervous System Infections in Children and Adults: Current Update. Antibiotics 2022, 11, 173. [Google Scholar] [CrossRef]
  80. Vergin, H.; Bishop-Freudling, G.; Foing, N.; Szelenyi, I.; Armengaud, H.; van Tho, T. Diffusion of Metioprim, Tetroxoprim and Sulphadiazine in the Cerebrospinal Fluid of Dogs with Healthy Meninges and Dogs with Experimental Meningitis. Chemotherapy 1984, 30, 297–304. [Google Scholar] [CrossRef]
  81. Nau, R.; Sörgel, F.; Eiffert, H. Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System Infections. Clin. Microbiol. Rev. 2010, 23, 858–883. [Google Scholar] [CrossRef] [PubMed]
  82. Dingsdag, S.A.; Hunter, N. Metronidazole: An update on metabolism, structure-cytotoxicity and resistance mechanisms. J. Antimicrob. Chemother. 2018, 73, 265–279. [Google Scholar] [CrossRef] [PubMed]
  83. Pan, Y.; Yi, J.; Zhou, B.; Xie, S.; Chen, D.; Tao, Y.; Qu, W.; Liu, Z.; Huang, L.; Yuan, Z. Disposition and Residue Depletion of Metronidazole in Pigs and Broilers. Sci. Rep. 2017, 7, 7203. [Google Scholar] [CrossRef] [PubMed]
  84. Szultka, M.; Krzeminski, R.; Jackowski, M.; Buszewski, B. Identification of In Vitro Metabolites of Amoxicillin in Human Liver Microsomes by LC–ESI/MS. Chromatographia 2014, 77, 1027–1035. [Google Scholar] [CrossRef] [PubMed]
  85. Zhou, Q.; Xiao, Q.; Zhang, Y.; Wang, X.; Xiao, Y.; Shi, D. Pig liver esterases PLE1 and PLE6: Heterologous expression, hydrolysis of common antibiotics and pharmacological consequences. Sci. Rep. 2019, 9, 15564. [Google Scholar] [CrossRef]
  86. Boothe, D.M.; Boeckh, A.; Boothe, H.W.; Wilkie, S. Tissue concentrations of enrofloxacin and ciprofloxacin in anesthetized dogs following single intravenous administration. Vet. Ther. 2001, 2, 120–128. [Google Scholar] [PubMed]
  87. Hwang, Y.H.; Kim, M.S.; Song, I.B.; Lim, J.H.; Park, B.K.; Yun, H.I. Altered pharmacokinetics of enrofloxacin in experimental models of hepatic and renal impairment. Vet. Res. Commun. 2008, 33, 481–487. [Google Scholar] [CrossRef]
  88. Demol, P.; Singer, M.; Bernemann, D.; Linzenmeier, G.; Goebell, H. Excretion of Azlocillin and Mezlocillin by the Normal Pancreas and in Acute Pancreatitis in Dogs and Rats. Digestion 1983, 27, 93–99. [Google Scholar] [CrossRef]
  89. Foitzik, T.; Hotz, H.G.; Kinzig, M.; Sörgel, F.; Buhr, H.J. Influence of changes in pancreatic tissue morphology and capillary blood flow on antibiotic tissue concentrations in the pancreas during the progression of acute pancreatitis. Gut 1997, 40, 526–530. [Google Scholar] [CrossRef]
  90. Brattström, C.; Tydén, G.; Malmborg, A.S.; Lundgren, G.; Ost, L.; Groth, C.G. Studies of the exocrine secretion of segmental pancreatic grafts with special reference to the diagnosis of rejection and to the penetration of drugs into the pancreatic juice. Transplant. Proc. 1987, 19, 2332–2335. [Google Scholar]
  91. Trudel, J.L.; Thompson, A.G.; Brown, R.A. Prophylactic use of antibiotics in pancreatic sepsis: A 25-year reappraisal. Can. J. Surg. 1984, 27, 567–570. [Google Scholar] [PubMed]
  92. Thaela, M.J.; Pierzynowski, S.G.; Jensen, M.S.; Jakobsen, K.; Weström, B.R.; Karlsson, B.W. The pattern of the circadian rhythm of pancreatic secretion in fed pigs. J. Anim. Sci. 1995, 73, 3402–3408. [Google Scholar] [CrossRef] [PubMed]
  93. García-Barrasa, A.; Borobia, F.G.; Pallares, R.; Jorba, R.; Poves, I.; Busquets, J.; Fabregat, J. A Double-blind, Placebo-controlled Trial of Ciprofloxacin Prophylaxis in Patients with Acute Necrotizing Pancreatitis. J. Gastrointest. Surg. 2008, 13, 768–774. [Google Scholar] [CrossRef] [PubMed]
  94. Wiuff, C.; Lykkesfeldt, J.; Aarestrup, F.M.; Svendsen, O. Distribution of enrofloxacin in intestinal tissue and contents of healthy pigs after oral and intramuscular administrations. J. Vet. Pharmacol. Ther. 2002, 25, 335–342. [Google Scholar] [CrossRef]
Figure 1. Illustration of the well-known enterohepatic recirculation pathway for bile acids and other molecules (orange) and the proposed enteropancreatic recirculation of some antibiotics and possibly other molecules (yellow). The arrows indicate direction of blood flow in the veins and arteries.
Figure 1. Illustration of the well-known enterohepatic recirculation pathway for bile acids and other molecules (orange) and the proposed enteropancreatic recirculation of some antibiotics and possibly other molecules (yellow). The arrows indicate direction of blood flow in the veins and arteries.
Antibiotics 13 00012 g001
Figure 2. Concentrations of nystatin in plasma and PES after administration of 40 mg/kg (200,000 units/kg) directly into the duodenum.
Figure 2. Concentrations of nystatin in plasma and PES after administration of 40 mg/kg (200,000 units/kg) directly into the duodenum.
Antibiotics 13 00012 g002
Figure 3. (A) Concentrations of metronidazole in plasma and PES after administration of 25 mg/kg directly into the duodenum. (B) Ratios calculated as the quotient of concentrations of metronidazole in the PES divided by plasma averaged 3.1 ± 0.5, indicative of concentrative secretion.
Figure 3. (A) Concentrations of metronidazole in plasma and PES after administration of 25 mg/kg directly into the duodenum. (B) Ratios calculated as the quotient of concentrations of metronidazole in the PES divided by plasma averaged 3.1 ± 0.5, indicative of concentrative secretion.
Antibiotics 13 00012 g003
Figure 4. (A) Concentrations of enrofloxacin in plasma and PES after the administration of 5 mg/kg directly into the duodenum and (B) intramuscular administration of 2.5 mg/kg. (C) Ratios calculated as the quotient of concentrations of enrofloxacin in the PES divided by plasma after administration into the duodenum or intramuscular averaged 3.1 + 0.5, indicative of concentrative secretion. Asterisks indicate ratios differed significantly between intramuscular and duodenal routes of administration.
Figure 4. (A) Concentrations of enrofloxacin in plasma and PES after the administration of 5 mg/kg directly into the duodenum and (B) intramuscular administration of 2.5 mg/kg. (C) Ratios calculated as the quotient of concentrations of enrofloxacin in the PES divided by plasma after administration into the duodenum or intramuscular averaged 3.1 + 0.5, indicative of concentrative secretion. Asterisks indicate ratios differed significantly between intramuscular and duodenal routes of administration.
Antibiotics 13 00012 g004aAntibiotics 13 00012 g004b
Figure 5. Concentrations of amoxicillin in plasma and PES after administration of 45 mg/kg directly into the duodenum.
Figure 5. Concentrations of amoxicillin in plasma and PES after administration of 45 mg/kg directly into the duodenum.
Antibiotics 13 00012 g005
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Buddington, K.K.; Pierzynowski, S.G.; Holmes, W.E.; Buddington, R.K. Selective and Concentrative Enteropancreatic Recirculation of Antibiotics by Pigs. Antibiotics 2024, 13, 12. https://doi.org/10.3390/antibiotics13010012

AMA Style

Buddington KK, Pierzynowski SG, Holmes WE, Buddington RK. Selective and Concentrative Enteropancreatic Recirculation of Antibiotics by Pigs. Antibiotics. 2024; 13(1):12. https://doi.org/10.3390/antibiotics13010012

Chicago/Turabian Style

Buddington, Karyl K., Stefan G. Pierzynowski, William E. Holmes, and Randal K. Buddington. 2024. "Selective and Concentrative Enteropancreatic Recirculation of Antibiotics by Pigs" Antibiotics 13, no. 1: 12. https://doi.org/10.3390/antibiotics13010012

APA Style

Buddington, K. K., Pierzynowski, S. G., Holmes, W. E., & Buddington, R. K. (2024). Selective and Concentrative Enteropancreatic Recirculation of Antibiotics by Pigs. Antibiotics, 13(1), 12. https://doi.org/10.3390/antibiotics13010012

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop